Ohcanbohtosat - Shanu Modi

Aiddostahte ozu
  1. 1
    Ganetespib: research and clinical development

    Ganetespib: research and clinical development Dahkki Shanu Modi, Komal Jhaveri

    Almmustuhtton 2015
    Viečča ollesdeavstta Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  2. 2
    HER2 breast cancer therapies: a review

    HER2 breast cancer therapies: a review Dahkki Shanu Modi, Conleth G. Murphy

    Almmustuhtton 2009
    Viečča ollesdeavstta Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  3. 3
    Unlocking the potential of antibody–drug conjugates for cancer therapy

    Unlocking the potential of antibody–drug conjugates for cancer therapy Dahkki Joshua Z. Drago, Shanu Modi, Sarat Chandarlapaty

    Almmustuhtton 2021
    Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  4. 4
    Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions

    Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions Dahkki Emanuela Ferraro, Joshua Z. Drago, Shanu Modi

    Almmustuhtton 2021
    Viečča ollesdeavstta Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  5. 5
    Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers

    Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers Dahkki Komal Jhaveri, Tony Taldone, Shanu Modi, Gabriela Chiosis

    Almmustuhtton 2011
    Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  6. 6
    Advances in the discovery and development of heat-shock protein 90 inhibitors for cancer treatment

    Advances in the discovery and development of heat-shock protein 90 inhibitors for cancer treatment Dahkki Hardik Patel, Shanu Modi, Gabriela Chiosis, Tony Taldone

    Almmustuhtton 2011
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  7. 7
    Beyond HER2: Targeting the ErbB receptor family in breast cancer

    Beyond HER2: Targeting the ErbB receptor family in breast cancer Dahkki Joshua Z. Drago, Emanuela Ferraro, Nour Abuhadra, Shanu Modi

    Almmustuhtton 2022
    Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  8. 8
    Incidence of chemotherapy‐induced, long‐term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane

    Incidence of chemotherapy‐induced, long‐term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane Dahkki Monica Fornier, Shanu Modi, Katherine S. Panageas, Larry Norton, Clifford A. Hudis

    Almmustuhtton 2005
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  9. 9
    Open questions, current challenges, and future perspectives in targeting human epidermal growth factor receptor 2-low breast cancer

    Open questions, current challenges, and future perspectives in targeting human epidermal growth factor receptor 2-low breast cancer Dahkki Giuseppe Curigliano, Rebecca Dent, H. Earle, Shanu Modi, Paolo Tarantino, Giulia Viale, Sara M. Tolaney

    Almmustuhtton 2024
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  10. 10
    Chaperome heterogeneity and its implications for cancer study and treatment

    Chaperome heterogeneity and its implications for cancer study and treatment Dahkki Tai Wang, Anna Rodina, Mark Dunphy, Adriana Corben, Shanu Modi, Mónica L. Guzmán, D.T. Gewirth, Gabriela Chiosis

    Almmustuhtton 2018
    Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  11. 11
    A phase 1 study of weekly dosing of trastuzumab emtansine (T‐DM1) in patients with advanced human epidermal growth factor 2–positive breast cancer

    A phase 1 study of weekly dosing of trastuzumab emtansine (T‐DM1) in patients with advanced human epidermal growth factor 2–positive breast cancer Dahkki Muralidhar Beeram, Ian E. Krop, Howard A. Burris, Sandhya Girish, Wei Yu, Michael W. Lu, Scott N. Holden, Shanu Modi

    Almmustuhtton 2012
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  12. 12
    Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer

    Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer Dahkki Ian E. Krop, Shanu Modi, Patricia LoRusso, Mark D. Pegram, Ellie Guardino, Betsy Althaus, Dan Lu, Alexander Strasak, Anthony Elias

    Almmustuhtton 2016
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  13. 13
    Endocrine Therapy–Induced Alopecia in Patients With Breast Cancer

    Endocrine Therapy–Induced Alopecia in Patients With Breast Cancer Dahkki Azael Freites‐Martínez, Jerry Shapiro, Donald Chan, Monica Fornier, Shanu Modi, Devika Gajria, Stephen W. Dusza, Shari Goldfarb, Mario E. Lacouture

    Almmustuhtton 2018
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  14. 14
    Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies

    Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies Dahkki Paolo Tarantino, Roberto Carmagnani Pestana, Chiara Corti, Shanu Modi, Aditya Bardia, Sara M. Tolaney, Javier Cortés, Jean‐Charles Soria, Giuseppe Curigliano

    Almmustuhtton 2021
    Viečča ollesdeavstta Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  15. 15
    The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation

    The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation Dahkki T. Jonathan Yang, Monica Morrow, Shanu Modi, Zhigang Zhang, Kate Krause, Chun Siu, Beryl McCormick, Simon N. Powell, Alice Y. Ho

    Almmustuhtton 2015
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  16. 16
    A Reversible Case of Advanced Interstitial Lung Disease in a Patient with HER2 Low Metastatic Breast Cancer Treated with Trastuzumab Deruxtecan

    A Reversible Case of Advanced Interstitial Lung Disease in a Patient with HER2 Low Metastatic Breast Cancer Treated with Trastuzumab Deruxtecan Dahkki Felipe Marques da Costa, Milena Tenório Cerezoli, Augusto Kreling Medeiros, Gabriela Machado Novaes, B.R. da Silva, Fernando Cotait Maluf, Shanu Modi

    Almmustuhtton 2023
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  17. 17
    A Phase I Dose-Escalation Trial of Trastuzumab and Alvespimycin Hydrochloride (KOS-1022; 17 DMAG) in the Treatment of Advanced Solid Tumors

    A Phase I Dose-Escalation Trial of Trastuzumab and Alvespimycin Hydrochloride (KOS-1022; 17 DMAG) in the Treatment of Advanced Solid Tumors Dahkki Komal Jhaveri, Kathy D. Miller, Lee S. Rosen, Bryan P. Schneider, Linnea Chap, Alison L. Hannah, Ziyang Zhong, Weining Ma, Clifford A. Hudis, Shanu Modi

    Almmustuhtton 2012
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  18. 18
    A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer

    A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer Dahkki Shanu Modi, Cristina Saura, Charles Henderson, Nancy U. Lin, Reshma Mahtani, Jill Goddard, Eduard Ródenas‐Alesina, Clifford A. Hudis, Joyce O’Shaughnessy, José Baselga

    Almmustuhtton 2013
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  19. 19
    Trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2–expressing salivary gland carcinoma: a pooled analysis of two phase I studies

    Trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2–expressing salivary gland carcinoma: a pooled analysis of two phase I studies Dahkki Shunji Takahashi, Hideaki Bando, Ichiro Kinoshita, Shanu Modi, Junji Tsurutani, Yung‐Jue Bang, Yuta Sato, Shunsuke Nakatani, Caleb Lee, Masahiro Sugihara, Yasuyuki Okuda, Hiroji Iwata

    Almmustuhtton 2024
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  20. 20
    Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast Cancer

    Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast Cancer Dahkki Sarat Chandarlapaty, Rita A. Sakr, Dilip D. Giri, Sujata Patil, Adriana Heguy, Monica Morrow, Shanu Modi, Larry Norton, Neal Rosen, Clifford A. Hudis, Tari A. King

    Almmustuhtton 2012
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:

Ohcanreaiddut: